News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly TST trial results: lower LDL-C target benefits ASCVD patients Endothelial LDL transcytosis in atherosclerosis Emerging lipid science: ApoE and chronic disease ODYSSEY: Alirocumab decreases stroke risk in ACS patients ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Download Now: New Slide Deck Programme

Slide decks focusing on key results and expert analysis from FOURIER, ODYSSEY OUTCOMES and ODYSSEY trials – all landmark trials in PCSK9 inhibition.

Find out more »

Download NowUNIQUE FREE APPAdvances in lipid lowering - a clinical guide

AHA Scientific Sessions 2019

16-18 November, Philadelphia, USA
ORION-9: durable and potent LDL-C lowering in HeFH patients on twice yearly dosing
ORION-10: effective LDL-C lowering in patients with ASCVD with twice yearly dosing
FOURIER: effects of evolocumab on cognition and following MI

ESC Congress 2019 with World Congress of Cardiology

EVOPACS: Evolocumab in acute ACS
ORION-11 with inclisiran
LDL cholesterol goals go lower…

Most viewed

Hepatic lipid metabolism: Storage vs secretion Does one plaque characteristic fit all? FOURIER: effects of evolocumab on cognition and following MI ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors? TST trial results: lower LDL-C target benefits ASCVD patients New approaches to treatment of moderate hypertriglyceridemia and new therapeutic combinations Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins EVOPACS: Evolocumab lowers LDL cholesterol without safety issues in the acute ACS setting Guidance needed on LDL lowering in very high-risk patients Are we doing any better with familial hypercholesterolaemia care?

Most viewed

Hepatic lipid metabolism: Storage vs secretion

Hot Topics

News from the 11th Expert Meeting of the Editorial Board of PCSK9 Forum

LDL transcytosis in atherosclerosis: Professor Phil Shaul (Center for Pulmonary and Vascular Biology, University of Texas Southwestern Medical Center, Dallas, USA)

View the Webcast

Emerging lipid science – Apolipoprotein E and chronic disease: Professor Ruth Frikke-Schmidt (Rigshospitalet and Faculty of Health and Medical Sciences, University of Copenhagen, Denmark) discusses exciting research

View the Webcast

From the Editors

Are we doing any better with familial hypercholesterolaemia care?

Professor Eric Bruckert, Pitié-Salpêtrière Hospital, Paris, France

Has the care of this common inherited disorder, characterised by high cholesterol levels from birth, improved in the last 5 years? What can we learn from the only global registry?

Read the report
Insights from the EAS FHSC Registry, Prof. Eric Bruckert
Watch the video
Too little, too late: Prof. Raul Santos discusses the EAS FHSC Registry data
Watch the video
2019 ESC/EAS Dyslipidaemia Guidelines and FH, Prof. Eric Bruckert
Watch the video